Drugs / Fovinaciclib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07616427 | May 2026 → May 2028 expected | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05439499 | Mar 2022 → Sep 2024 | female breast carcinoma | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fovinaciclib | “Patients were randomized (1:1) to receive fovinaciclib, 200 mg (orally once daily on days 1 to 21), or placebo plus letrozole, 2.5 mg, or anastrozole, 1 mg (orally once daily...” PMID 42224659 ↗ Jun 2026 |
| Modality | Small molecule | — CHEMBL6068012 ↗ |
| Route | Oral | “FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach.” NCT05439499 ↗ |